209 related articles for article (PubMed ID: 23071721)
1. Role of corticotropin-releasing factor (CRF) receptor-1 on the catecholaminergic response to morphine withdrawal in the nucleus accumbens (NAc).
Almela P; Navarro-Zaragoza J; García-Carmona JA; Mora L; Hidalgo J; Milanés MV; Laorden ML
PLoS One; 2012; 7(10):e47089. PubMed ID: 23071721
[TBL] [Abstract][Full Text] [Related]
2. Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal.
Navarro-Zaragoza J; Núñez C; Laorden ML; Milanés MV
Mol Pharmacol; 2010 May; 77(5):864-73. PubMed ID: 20159948
[TBL] [Abstract][Full Text] [Related]
3. Cardiac adverse effects of naloxone-precipitated morphine withdrawal on right ventricle: role of corticotropin-releasing factor (CRF) 1 receptor.
Navarro-Zaragoza J; Martínez-Laorden E; Mora L; Hidalgo J; Milanés MV; Laorden ML
Toxicol Appl Pharmacol; 2014 Feb; 275(1):28-35. PubMed ID: 24398105
[TBL] [Abstract][Full Text] [Related]
4. CRF₂ mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats.
Navarro-Zaragoza J; Núñez C; Ruiz-Medina J; Laorden ML; Valverde O; Milanés MV
Br J Pharmacol; 2011 Feb; 162(4):851-62. PubMed ID: 20973778
[TBL] [Abstract][Full Text] [Related]
5. Restricted role of CRF1 receptor for the activity of brainstem catecholaminergic neurons in the negative state of morphine withdrawal.
Garcia-Carmona JA; Almela P; Baroja-Mazo A; Milanes MV; Laorden ML
Psychopharmacology (Berl); 2012 Mar; 220(2):379-93. PubMed ID: 21947312
[TBL] [Abstract][Full Text] [Related]
6. Conditioned aversive memory associated with morphine withdrawal increases brain-derived neurotrophic factor in dentate gyrus and basolateral amygdala.
Martínez-Laorden E; Navarro-Zaragoza J; Milanés MV; Laorden ML; Almela P
Addict Biol; 2020 Jul; 25(4):e12792. PubMed ID: 31282111
[TBL] [Abstract][Full Text] [Related]
7. Corticotropin-releasing factor 1 receptor mediates the activity of the reward system evoked by morphine-induced conditioned place preference.
Lasheras MC; Laorden ML; Milanés MV; Núñez C
Neuropharmacology; 2015 Aug; 95():168-80. PubMed ID: 25556110
[TBL] [Abstract][Full Text] [Related]
8. Corticotropin-releasing factor (CRF) receptor-1 is involved in cardiac noradrenergic activity observed during naloxone-precipitated morphine withdrawal.
Martínez-Laorden E; García-Carmona JA; Baroja-Mazo A; Romecín P; Atucha NM; Milanés MV; Laorden ML
Br J Pharmacol; 2014 Feb; 171(3):688-700. PubMed ID: 24490859
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence.
Lu L; Liu D; Ceng X; Ma L
Eur J Neurosci; 2000 Dec; 12(12):4398-404. PubMed ID: 11122350
[TBL] [Abstract][Full Text] [Related]
10. Accumbal dopamine, noradrenaline and serotonin activity after naloxone-conditioned place aversion in morphine-dependent mice.
Gómez-Milanés I; Almela P; García-Carmona JA; García-Gutiérrez MS; Aracil-Fernández A; Manzanares J; Milanés Maquilón MV; Laorden ML
Neurochem Int; 2012 Aug; 61(3):433-40. PubMed ID: 22713675
[TBL] [Abstract][Full Text] [Related]
11. Morphine administration modulates expression of Argonaute 2 and dopamine-related transcription factors involved in midbrain dopaminergic neurons function.
García-Pérez D; Sáez-Belmonte F; Laorden ML; Núñez C; Milanés MV
Br J Pharmacol; 2013 Apr; 168(8):1889-901. PubMed ID: 23215787
[TBL] [Abstract][Full Text] [Related]
12. Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal.
Chartoff EH; Mague SD; Barhight MF; Smith AM; Carlezon WA
J Neurosci; 2006 Jun; 26(24):6450-7. PubMed ID: 16775132
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
Navarro-Zaragoza J; Laorden ML; Milanés MV
Toxicology; 2014 Dec; 326():36-43. PubMed ID: 25308750
[TBL] [Abstract][Full Text] [Related]
14. Morphine withdrawal activates hypothalamic-pituitary-adrenal axis and heat shock protein 27 in the left ventricle: the role of extracellular signal-regulated kinase.
Martínez-Laorden E; Hurle MA; Milanés MV; Laorden ML; Almela P
J Pharmacol Exp Ther; 2012 Sep; 342(3):665-75. PubMed ID: 22647273
[TBL] [Abstract][Full Text] [Related]
15. Morphine withdrawal-induced c-fos expression in the hypothalamic paraventricular nucleus is dependent on the activation of catecholaminergic neurones.
Laorden ML; Núñez C; Almela P; Milanés MV
J Neurochem; 2002 Oct; 83(1):132-40. PubMed ID: 12358736
[TBL] [Abstract][Full Text] [Related]
16. Regulation of dopaminergic markers expression in response to acute and chronic morphine and to morphine withdrawal.
García-Pérez D; Núñez C; Laorden ML; Milanés MV
Addict Biol; 2016 Mar; 21(2):374-86. PubMed ID: 25522207
[TBL] [Abstract][Full Text] [Related]
17. Regulation of tyrosine hydroxylase levels and activity and Fos expression during opioid withdrawal in the hypothalamic PVN and medulla oblongata catecholaminergic cell groups innervating the PVN.
Benavides M; Laorden ML; García-Borrón JC; Milanés MV
Eur J Neurosci; 2003 Jan; 17(1):103-12. PubMed ID: 12534973
[TBL] [Abstract][Full Text] [Related]
18. Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal.
Fuertes G; Laorden ML; Milanés MV
Neuroendocrinology; 2000 Jan; 71(1):60-7. PubMed ID: 10644900
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tyrosine hydroxylase phosphorylation in the nucleus accumbens and nucleus tractus solitarius-A2 cell group after morphine-conditioned place preference.
González-Cuello A; Mora L; Hidalgo JM; Meca N; Lasheras C; Milanés MV; Laorden ML
Naunyn Schmiedebergs Arch Pharmacol; 2010 Dec; 382(5-6):525-34. PubMed ID: 20924561
[TBL] [Abstract][Full Text] [Related]
20. Nucleus accumbens D2- and D1-receptor expressing medium spiny neurons are selectively activated by morphine withdrawal and acute morphine, respectively.
Enoksson T; Bertran-Gonzalez J; Christie MJ
Neuropharmacology; 2012 Jun; 62(8):2463-71. PubMed ID: 22410393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
